Genentech reports detailed Phase III data for Tecentriq plus Avastin in first-line RCC

The Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) reported additional data from the Phase III IMmotion151 trial in 915 patients with renal cell carcinoma (RCC) evaluating first-line treatment with 1,200 mg IV Tecentriq atezolizumab (MPDL3280A, RG7446) plus Avastin bevacizumab every

Read the full 403 word article

User Sign In